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Abstract: Continuous low-dose release of the GnRH analogue deslorelin (Suprelorin, Peptech, Australia) causes a 
suppression of reproductive function in different species such as dogs, koalas, or kangaroos. No studies concerning the 
effi cacy and safety in male rabbits have yet been conducted. A male rabbit with hypospadia was introduced to the Clinic 
for Animal Reproduction. The owner intended to keep it together with a fertile female rabbit. To avoid reproduction, a 4.7 
mg deslorelin implant was injected subcutaneously. No negative reaction to implant placement was diagnosed by daily 
examination of the injection site for one week. To test the effectiveness of the treatment, blood samples were taken and 
the testes size was measured regularly. After an initial rise in testosterone levels for 14 d, a down regulation for seven 
month with values lower than 0.1 ng/mL was observed. In the same period, the size of the testes declined to 50 % of the 
original dimensions. Afterwards, both testes regained their former shape and size. Since it was not a stud rabbit, semen 
parameters were not determined. During the suppression of the reproductive function, no sexual activity was observed 
by the owners. These fi ndings have yet to be proven by clinical trials with a suffi cient number of animals, but this case 
indicates the effi cacy of deslorelin implants in male rabbits.
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INTRODUCTION
Rabbits are increasingly kept as pets. Since rabbits are considered highly social creatures, many authors 
suggest keeping them in companion with another rabbit (Harcourt-Brown, 2004). Consequently, the 
owners often request neutering of one or both of the rabbits to prevent reproduction (More, 1999). 
Other reasons for neutering male rabbits are hypersexuality (e.g. attempts to mate the owner’s legs), 
territory marking (spraying of urine or depositing faeces) and aggression against other rabbits or humans. 
Currently, male and – to a lower extent – female rabbits are neutered (spayed or castrated) surgically. A 
mortality rate of 1.4 per cent in rabbits undergoing anaesthesia (Brodbelt et al., 2008) and additional risks 
of intra- and post-operative complications have to be considered. 
Some research-based recommendations on alternative, safe and effective techniques for prevention 
of reproduction in male rabbits have been published (Williams, 1980; Lohiyaa et al., 1999), but with 
unsatisfactory results. In general, tested strategies for anti-fertility agents for male animals that are long-
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acting, reliable and free of side effects have focused on administration of reproductive hormones and their 
analogues and on vaccination against antigens in the reproductive process (Trigg et al., 2001). 
Recently, slow-release biocompatible implants containing deslorelin have provided an opportunity 
for effective contraception for male dogs (Junaidi et al., 2003), mice (Kher and Kalla, 1996), ferrets 
(Schoemaker et al., 2008), koalas (Herbert et al., 2001), Tammar wallabies (Herbert et al., 2004) and 
other species. As yet, no adverse effects have been reported (Trigg et al., 2006). Deslorelin is a D-Trp6-
Pro6-des Gly10GnRH analogue with two amino acid substitutions (Kutzler, 2007). Modification of the 
peptides results in an increase in resistance to peptidases and enhances receptor binding affinity. Thus, 
GnRH agonists have a longer half-life in circulation and are up to 200 times more potent than native 
GnRH (Herbert and Trigg, 2005). 
Initially, long-acting GnRH agonists induce a significant increase in LH and FSH concentrations in male 
and female dogs, which can last for several days ( Herbert and Trigg, 2005). Subsequently, the continued 
exposure to GnRH agonists suppresses the secretion of LH and FSH as a consequence of down regulation 
of GnRH receptors on gonadotrope cells of the pituitary (Hazum and Conn, 1988). Without the stimulating 
effect of FSH and LH, the gonads no longer produce gonadal steroids.
The deslorelin implant Suprelorin has been marketed since 2004 in Australia and New Zealand since 
2005. It is formulated as a cylindrical implant in a preloaded syringe for subcutaneous implantation. In 
2008, Suprelorin 4.7 mg was approved for use in male dogs in several European Union countries and is 
available via Virbac Animal Health (Carros Cedex, France). 
To our knowledge, no studies concerning the efficacy and safety in male rabbits have yet been published. 
MATERIALS AND METHODS
A 12 mo old male rabbit (breed: Loh rabbit) weighing 3.2 kg with a high-grade penile hypospadia 
was introduced to the Clinic for Animal Reproduction in spring 2008. Hypospadia is a defect of the 
urethra with a ventral opening in a line instead of an opening at the tip of the penis. It can be induced 
pharmacologically and genetic factors are likely to be involved in most cases (Kurzrock et al., 2000). The 
owner intended to house it together with a fertile female rabbit but refused surgical castration.
To avoid reproduction, a 4.7 mg deslorelin Implant (Suprelorin, Peptech, North Ryde, Australia) was 
injected subcutaneously into the dorsal skin of the neck on April 7th 2008. Before treatment, an informed 
consent by the owner including the fact that the rabbit will not be suitable for human consumption was 
obtained and signed. 
No negative reaction to the implant placement was diagnosed by daily examination of the injection site 
for one week. To estimate the efficacy of the treatment, repeated blood samples were taken in the first 
four weeks after administration and afterwards at monthly intervals. Blood was drawn from auricular 
vein or from vena cephalica. Serum was centrifuged at 1500 g and submitted to a commercial laboratory 
to determine testosterone concentrations by ECLIA (Elektrochemiluminescence Immunoassay, Cobas 
6000, Roche Diagnostics, Rotkreuz, Switzerland). Furthermore, the size of the testes (including testis and 
epididymis) was measured regularly with a sliding calliper. 
RESULTS
Serum testosterone concentration immediately before implantation of the bolus in May 2008 was 3.4 ng/
mL, which is in agreement with the reference range of 0.4-4.6 ng/mL as reported by Artega et al. (2008). 
After an initial rise of testosterone concentration to 5.5 ng/mL, 9 d after the administration a temporary 
down regulation with values lower than 0.1 ng/mL was observed (Figure 1). In the same period, the length 
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of both testes (4.0 cm before administration of the deslorelin implant) declined to approximately 2.0 cm, 
which represents 50 % of the original dimensions. 
After a period of 7 mo (June to December), the testosterone concentration increased again and reached 
3.1 ng/mL in March 2009. Corresponding with the increase in testosterone concentrations, we observed 
a re-growth of the testes during the last 2 mo of the observation period. Length of the testes was 3.9 cm 
in March 2009. The diameter of the testes remained almost constant throughout the observation period. 
Eight weeks after treatment, the male rabbit was co-housed with the female rabbit. During the suppression 
of the reproductive function, no sexual activity was observed by the owners and no offspring occurred. 
Since it was not a stud rabbit, semen parameters were not determined. 
By the end of the observation period, the owner had changed his housing concept and consequently 
another injection was not necessary.
DISCUSSION
This case report indicates that the deslorelin implant was effective in decreasing testosterone concentrations 
to basal levels. Because semen parameters were not assessed, the effect of the deslorelin implant on 
fertility cannot be evaluated, but it is likely that the observed suppression of testosterone and decrease in 
testes size corresponded to a discontinued spermatogenesis. This effect of deslorelin implants has been 
demonstrated in dogs (Junaidi et al., 2003), kangaroos (Herbert et al., 2004), and other species. The 
co-housing with a fertile female rabbit did not result in undesired offspring. Regarding the subsequent 
increase in testosterone and re-growth of the testes, it can be presumed that semen characteristics had 
recovered completely. The complete recovery of male fertility has been demonstrated in dogs (Junaidi et 
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Surgical castration reduces testosterone-dependent aggression among males (Arteaga et al., 2008), 
reduces the size and secretory activity of the chin gland, and reduces or eliminates territory marking 
(Girolami et al., 1997). Hence, it seems that these conditions might also be influenced by administration 
of a deslorelin implant, with a consequent decline in serum testosterone concentrations.
We conclude that the single, slow-release implant containing 4.7 mg deslorelin caused a long-term, 
reversible suppression of sexual function in the male rabbit. It remains open whether this technique leads 
to a safe and complete suppression of reproductive function without a remaining risk of mating during the 
pharmacological activity of the implant. The authors received anecdotal information of non-efficacy of 
the implant in single cases. In order to make an evidence-based recommendation, efficacy, reliability and 
safety have to be proven by clinical trials with a sufficient number of animals.
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